CTLA-4 blockade was shown to inhibit tumor progression by upregulating effector T-cell activity and suppress regulatory T cells (Tregs), which suggest that the patients with high-risk score of the 7-gene prognostic signature might benefit less from CTLA-4 blockade therapy. Here, CTLA4 is linked to neoplasm.